Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study
Wille K, Stegelmann F, Busen H, Fuchs C, Schauer S, Sadjadian P, Becker T, Kolatzki V, Doehner H, Doehner K, Griesshammer M (2019)
In: ONCOLOGY RESEARCH AND TREATMENT., 42(Suppl. 4). Basel: Karger: 96.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Wille, K.;
Stegelmann, F.;
Busen, H.;
Fuchs, ChristianeUniBi 
;
Schauer, S.;
Sadjadian, P.;
Becker, T.;
Kolatzki, V.;
Doehner, H.;
Doehner, K.;
Griesshammer, M.
;
Schauer, S.;
Sadjadian, P.;
Becker, T.;
Kolatzki, V.;
Doehner, H.;
Doehner, K.;
Griesshammer, M.Erscheinungsjahr
2019
Titel des Konferenzbandes
ONCOLOGY RESEARCH AND TREATMENT
Band
42
Ausgabe
Suppl. 4
Seite(n)
96
ISSN
2296-5270
eISSN
2296-5262
Page URI
https://pub.uni-bielefeld.de/record/2946521
Zitieren
Wille K, Stegelmann F, Busen H, et al. Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. In: ONCOLOGY RESEARCH AND TREATMENT. Vol 42. Basel: Karger; 2019: 96.
Wille, K., Stegelmann, F., Busen, H., Fuchs, C., Schauer, S., Sadjadian, P., Becker, T., et al. (2019). Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. ONCOLOGY RESEARCH AND TREATMENT, 42, 96. Basel: Karger.
Wille, K., Stegelmann, F., Busen, H., Fuchs, Christiane, Schauer, S., Sadjadian, P., Becker, T., et al. 2019. “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study”. In ONCOLOGY RESEARCH AND TREATMENT, 42:96. Basel: Karger.
Wille, K., Stegelmann, F., Busen, H., Fuchs, C., Schauer, S., Sadjadian, P., Becker, T., Kolatzki, V., Doehner, H., Doehner, K., et al. (2019). “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study” in ONCOLOGY RESEARCH AND TREATMENT, vol. 42, (Basel: Karger), 96.
Wille, K., et al., 2019. Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. In ONCOLOGY RESEARCH AND TREATMENT. no.42 Basel: Karger, pp. 96.
K. Wille, et al., “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study”, ONCOLOGY RESEARCH AND TREATMENT, vol. 42, Basel: Karger, 2019, pp.96.
Wille, K., Stegelmann, F., Busen, H., Fuchs, C., Schauer, S., Sadjadian, P., Becker, T., Kolatzki, V., Doehner, H., Doehner, K., Griesshammer, M.: Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. ONCOLOGY RESEARCH AND TREATMENT. 42, p. 96. Karger, Basel (2019).
Wille, K., Stegelmann, F., Busen, H., Fuchs, Christiane, Schauer, S., Sadjadian, P., Becker, T., Kolatzki, V., Doehner, H., Doehner, K., and Griesshammer, M. “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study”. ONCOLOGY RESEARCH AND TREATMENT. Basel: Karger, 2019.Vol. 42. 96.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar